Get All Access for $5/mo

3 Pharmaceutical Stocks to Buy and Hold for the Long Haul Robust pipelines make these three pharmaceutical stocks solid choices for investors looking for stocks to buy and hold for long-term gains

By Chris Markoch

This story originally appeared on MarketBeat

There's a reason why many investors own one or more pharmaceutical stocks. This is a $1.2 trillion industry that is essential to the quality of life for many people. And every year, companies in this sector are getting closer to real breakthroughs in areas like diabetes, cancer, even Alzheimer's Disease.

The real payoff for these new drugs may be years away. But a compelling feature of any pharmaceutical stocks is a stable dividend that can deliver shareholder value while these drugs advance through a company's pipeline.

That's the case with the three pharmaceutical stocks on this list. Each of these are solid choices for investors looking for stocks to buy and hold for long-term gains.

A Robust Pipeline Gives Investors Many Bites at the Apple

Shares of Pfizer, Inc. (NYSE: PFE) are down 26% in the last 12 months and the stock is now down over 10% in the last five years. So much for the bump the stock got from its Covid-19 vaccine and therapeutic when it reached an all-time high of over $59 on December 31, 2021.

Of course, there's a reason why PFE stock is lower. That is, demand for its Covid-related products is declining. So investors need other reasons to buy this undervalued stock. And there are several in place.

For starters, the company has a deep pipeline of 90 candidates that includes over 30 that are either in Phase 3 trials or are waiting on regulatory approval. And Pfizer merged with Seagen Inc. (NASDAQ: SGEN) in March. The $43 billion transaction may weigh on earnings in the short term, but it gives the pharmaceutical giant access to Seagen's portfolio of oncology drugs. Pfizer expects this to add $10 billion to the company's revenue by 2030.

And as of August 11, 2023, you can buy PFE stock at a forward P/E ratio of 10x earnings with a dividend that has an attractive yield of 4.59%.

Competition Shouldn't Steer You Away from This Dividend King

AbbVie, Inc. (NYSE: ABBV) is another pharmaceutical stock to consider as a buy-and-hold candidate. ABBV stock is up 6% in the last 12 months. That's almost identical to the performance of the S&P 500 index over the same period. However, in 2023, AbbVie is down 6% which lags the broader market.

The issue weighing on AbbVie is that 2023 is the first year that its blockbuster drug Humira is facing biosimilar competition. However, while the company's first quarter revenue and earnings were lower on a year-over-year basis, the company also showed that Humira sales are holding up.

One reason for this is that AbbVie still has a patent thicket around Humira for several indications. This will keep competition at bay for several more years. And two new drugs, Skyrizi and Rinvoq, are helping to pick up the slack. Investors should also not overlook AbbVie's pipeline of over 90 candidates.

At 31x trailing earnings, ABBV stock doesn't look undervalued. But the forward P/E ratio is a reasonable 13x. Plus, investors are buying a Dividend King that has increased its dividend for 51 consecutive years and has a dividend yield of 3.91%.

This Blue-Chip Pharma Stock is On Sale

The story for the Bristol-Myers Squibb Company (NYSE: BMY) is similar to that of AbbVie and Pfizer. That is, the company's stock is down largely due to biosimilar competition for its cancer drug, Revlimid. In the last quarter, the company announced a 41.3% drop in revenue. That's an acceleration from the prior year.

However, this is also a pipeline story. In the case of Bristol-Myers Squibb, the pipeline contains over 50 candidates with several of those in Phase 3 studies. That bodes well for the long-term growth of the company.

BMY stock is currently trading at the low end of its 52-week range. This gives investors a nice entry point for a stock that has a forward P/E of around 8x and an extremely stable dividend that the company has increased for 16 consecutive years.

Want to be an Entrepreneur Leadership Network contributor? Apply now to join.

Editor's Pick

Business Solutions

Set up a Team Member with Microsoft Office 2021 for Windows for Just $50

Get great versions of Microsoft Excel, PowerPoint, Access, and other beloved programs.

Thought Leaders

10 Simple, Productive Activities You Can Do When You Aren't Motivated to Work

Quick note: This article is birthed out of the urge to do something productive when I am not in a working mood. It can also inspire you on simple yet productive things to do when you're not motivated to work.

Business Ideas

63 Small Business Ideas to Start in 2024

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2024.

Business News

Amazon Is Thinking About Charging Extra for AI Alexa

"Hey Alexa, how much are you going to cost?"

Making a Change

Invest in a Lifetime of Learning for $100

Skill Success features a wide variety of e-learning courses on business, finance, and more.


This Car Dash Display Is Only $90 Through June 26

Compatible with Apple CarPlay and Android Auto, this display is designed to make your commute safer.